FY 2025 Preliminary Unaudited Total Revenue of Approximately $510–511 Million Meets or Exceeds Prior Guidance Previously ...
Analysts have recently evaluated Haemonetics and provided 12-month price targets. The average target is $87.45, accompanied ...
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $246.25, a high ...
Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using ...
19h
Blue Dart Maps India’s 2025 Delivery Boom, Logs 2 Billion Km Road Haul & 47 Million Secure Parcels
On its busiest day in July 2025, Blue Dart moved over 14,000 tonnes of cargo—double its daily average. In total, 47 million ...
A new adaptive metaskin hides objects from thermal cameras in both hot and cold environments, automatically adjusting its ...
In patients with impaired renal function or fast-deteriorating eGFR at baseline, lucerastat was associated with a marked attenuation of kidney function loss, suggesting a potential disease-modifying e ...
AGCO brands Fendt, Massey Ferguson and PTx have earned a combined seven 2026 AE50 awards from the American Society of ...
In patients with impaired renal function or fast-deteriorating eGFR at baseline, lucerastat was associated with a marked ...
Detailed price information for Monte Rosa Therapeutics Inc (GLUE-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback